Glenmark Pharmaceuticals today announced receipt of approval from the US health regulator to sell its generic version of AbbVie Inc’s blood pressure drug Tarka in the American market.
The approval for trandolapril and verapamil hydrochloride extended release tablets has been granted to Glenmark Generics Inc, a subsidiary of Glenmark Generics Ltd.
Glenmark will commence distribution of trandolapril and verapamil hydrochloride tablets immediately. These will be available in strengths of 1mg/240mg, 2mg/180 mg, 2mg/240mg and 4mg/240 mg, the company said in a filing to the BSE.
AbbVie Inc’s Tarka is indicated for treatment of hypertension.
Citing IMS Health sales data, Glenmark said in the 12 months period ending December 2014, annual sales of Tarka stood at about $23.5 million.
The current portfolio of the company consists of 95 products authorised for distribution in the US and 74 ANDAs pending approval with the US health regulator, it added.
Shares of Glenmark Pharmaceuticals were trading at Rs 779.60 per scrip in morning trade, down 1.15 per cent from the previous close on the BSE.